The Beauty Health Company (NASDAQ: SKIN) reported Q3 EPS of ($0.56), $0.63 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $97.4 million versus the consensus estimate of $116.23 million.

GUIDANCE:

The Beauty Health Company sees FY2023 revenue of $385-400 million, versus the consensus of $461.3 million.

The Company revised its fiscal year 2023 net sales guidance due to provider experience challenges with Syndeo creating lower than expected demand for delivery systems in the U.S.
The Company revised its fiscal year 2023 adjusted EBITDA margin guidance as a result of slower than expected gross margin recovery and reduced fixed cost operating leverage.
The Company suspended its long-term fiscal year 2025 outlook.

For earnings history and earnings-related data on The Beauty Health Company (SKIN) click here.